Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (Aflac ST0901)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01331135|
Recruitment Status : Active, not recruiting
First Posted : April 7, 2011
Last Update Posted : July 17, 2017
The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy. These treatments can prolong their life but may not offer a long-term cure.
This study proposes using a drug called Sirolimus in combination with common chemotherapy drugs to treat patients with recurrent and refractory solid tumors. Sirolimus has been found to inhibit cell growth and to have anti-tumor activity in pediatric solid tumors in previous studies and, therefore, has the potential to increase the effectiveness of the chemotherapy drugs when given together.
This study wil investigate the highest dose of Sirolimus that can be given orally with other oral chemotherapy drugs. Cohorts of 2 subjects will be started at the minimum dose. The dose will be increased in the next 2 subjects as long as there were no major reactions in the previous groups. This study will also seek to learn more about the side effects of sirolimus when used in this combination and what effects the drug has on the white cells and the immune system. Successful use of this drug will impact the cancer population greatly by providing an increased chance of survival to those with resistant or recurrent cancers.
|Condition or disease||Intervention/treatment||Phase|
|Ewing's Sarcoma Osteosarcoma Astrocytoma Atypical Teratoid/Rhabdoid Tumor Ependymoma Germ Cell Tumor Glioma Medulloblastoma Rhabdoid Tumor Retinoblastoma Clear Cell Sarcoma Renal Cell Carcinoma Wilms Tumor Hepatoblastoma Neuroblastoma Rhabdomyosarcoma||Drug: sirolimus||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||August 2014|
|Estimated Study Completion Date :||April 2021|
Experimental: sirolimus treatment
Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
- Maximum tolerated dose (MTD) [ Time Frame: 2 years after treatment starts ]estimate the maximum tolerated dose (MTD) and recommended Phase II dose of sirolimus administered orally once daily for 42 days in combination with metronomic chemotherapy in children with recurrent or refractory solid tumors.
- define and describe toxicities of sirolimus [ Time Frame: 2 years post treatment ]To define and describe the toxicities of sirolimus administered in combination with metronomic chemotherapy administered according to this schedule.
- anti-tumor activity of sirolimus [ Time Frame: 2 years post treatment ]To assess the antitumor activity of sirolimus administered in combination with metronomic chemotherapy to children with recurrent and refractory solid tumors within the confines of a Phase I study.
- evaluate correlation of p70S6 kinase activity [ Time Frame: 2 years post treatment ]To evaluate the correlation of p70S6 kinase activity inhibition with tumor response.
- evaluate risk of infection [ Time Frame: 2 years post treatment ]To evaluate the effect of this combination therapy on lymphocyte subsets and memory T-cells, and to correlate that with risk of infection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01331135
|United States, Georgia|
|Children's Healthcare of Atlanta|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Muna Qayed, MD||Children's Healthcare of Atlanta|